0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Outbreak of Fusarium solani Meningitis in Immunocompetent Persons Associated With Neuraxial Blockade in Durango, Mexico, 2022–2023

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Fungal meningitis can be associated with epidural anesthesia procedures. Fusariosis is a rare infection typically affecting immunocompromised patients and rarely causes meningitis. During 2022–2023, public health officials responded to a large outbreak of Fusarium solani meningitis associated with epidural anesthesia in Durango, Mexico.

          Methods

          The public health response and epidemiological and clinical features of patients affected by this outbreak were described. Coordinated actions were addressed to identify the etiological agent, determine its drug susceptibility, develop diagnostic tests, and implement clinical and epidemiological protocols. Retrospective analyses of clinical variables and outcomes were performed to determine association with better patient survival.

          Results

          A total of 1801 persons exposed to epidural anesthesia were identified, of whom 80 developed meningitis. Fusarium solani was found in 3 brain biopsies and showed susceptibility to voriconazole and amphotericin B. After F solani polymerase chain reaction (PCR) implementation, 57 patients with meningitis were PCR-screened, and 31 (38.8%) had a positive result. Most patients were female (95%), and cesarean section was the most common surgical procedure (76.3%). The case fatality rate was 51.3% (41 patients) and the median hospitalization duration was 39.5 days (interquartile range, 18–86 days). Seventy-one patients (88.8%) received voriconazole/amphotericin B and 64 subjects (80%) additionally received steroids. Cox regression analysis showed an increased lethality risk in patients who received antifungal treatment after 5 days (hazard ratio, 2.1 [95% confidence interval, 1.01–4.48], P < .05).

          Conclusions

          The F solani meningitis outbreak in Durango was an unprecedented medical challenge. Timely treatment and effective healthcare management were associated with better survival outcomes.

          Abstract

          During 2022–2023, an outbreak of Fusarium solani–related meningitis occurred in Durango, Mexico, affecting 80 patients with a mortality of 51.3%. Prompt antifungal treatment and increased health awareness were associated with patient survival.

          Related collections

          Most cited references14

          • Record: found
          • Abstract: found
          • Article: not found

          Improvement in the outcome of invasive fusariosis in the last decade.

          Invasive fusariosis (IF) has been associated with a poor prognosis. Although recent series have reported improved outcomes, the definition of optimal treatments remains controversial. The objective of this study was to evaluate changes in the outcome of IF. We retrospectively analysed 233 cases of IF from 11 countries, comparing demographics, clinical findings, treatment and outcome in two periods: 1985-2000 (period 1) and 2001-2011 (period 2). Most patients (92%) had haematological disease. Primary treatment with deoxycholate amphotericin B was more frequent in period 1 (63% vs. 30%, p <0.001), whereas voriconazole (32% vs. 2%, p <0.001) and combination therapies (18% vs. 1%, p <0.001) were more frequent in period 2. The 90-day probabilities of survival in periods 1 and 2 were 22% and 43%, respectively (p <0.001). In period 2, the 90-day probabilities of survival were 60% with voriconazole, 53% with a lipid formulation of amphotericin B, and 28% with deoxycholate amphotericin B (p 0.04). Variables associated with poor prognosis (death 90 days after the diagnosis of fusariosis) by multivariable analysis were: receipt of corticosteroids (hazard ratio (HR) 2.11, 95% CI 1.18-3.76, p 0.01), neutropenia at end of treatment (HR 2.70, 95% CI 1.57-4.65, p <0.001), and receipt of deoxycholate amphotericin B (HR 1.83, 95% CI 1.06-3.16, p 0.03). Treatment practices have changed over the last decade, with an increased use of voriconazole and combination therapies. There has been a 21% increase in survival rate in the last decade.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Current antifungal treatment of fusariosis.

            Fungi of the genus Fusarium are well known as major plant pathogens and soil inhabitants, but also cause a broad spectrum of human infections. Fusariosis is the second most common mould infection after aspergillosis, and keratitis is the most encountered implantation infection in immunocompetent individuals. Natamycin is active against Fusarium species both in vitro and in vivo, and is used along with voriconazole as the mainstay of treatment for Fusarium keratitis. Onychomycosis is treated with terbinafine, voriconazole and sometimes itraconazole. Cure is possible despite high in vitro minimum inhibitory concentrations (MICs). Recently, disseminated infections have increased dramatically, mainly affecting severely immunocompromised patients. The remarkable intrinsic resistance of Fusarium species to most antifungal agents results in high mortality rates in this patient population. Recovery of neutropenia is essential for patient survival and treatment should include voriconazole or amphotericin B as first-line and posaconazole as salvage therapy.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Human fusariosis

                Bookmark

                Author and article information

                Contributors
                Journal
                Open Forum Infect Dis
                Open Forum Infect Dis
                ofid
                Open Forum Infectious Diseases
                Oxford University Press (US )
                2328-8957
                February 2024
                04 January 2024
                04 January 2024
                : 11
                : 2
                : ofad690
                Affiliations
                Dirección General de Epidemiología, Secretaría de Salud , Mexico City, Mexico
                Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social , Mexico City, Mexico
                Dirección de los Servicios de Salud del Estado de Durango, Secretaría de Salud , Durango, Mexico
                Dirección de Información Epidemiológica, Dirección General de Epidemiología, Secretaría de Salud , Mexico City, Mexico
                Coordinación de la Red Hospitalaria de Vigilancia Epidemiológica, Dirección de Información Epidemiológica, Secretaría de Salud , Mexico City, Mexico
                Coordinación de la Red Hospitalaria de Vigilancia Epidemiológica, Dirección de Información Epidemiológica, Secretaría de Salud , Mexico City, Mexico
                Coordinación de la Red Hospitalaria de Vigilancia Epidemiológica, Dirección de Información Epidemiológica, Secretaría de Salud , Mexico City, Mexico
                Coordinación de la Red Hospitalaria de Vigilancia Epidemiológica, Dirección de Información Epidemiológica, Secretaría de Salud , Mexico City, Mexico
                Servicio de Neurología, Hospital General 450, Servicios de Salud del Estado de Durango, Secretaría de Salud , Durango, Mexico
                Clínica de Infectología, Hospital General 450, Servicios de Salud del Estado de Durango, Secretaría de Salud , Durango, Mexico
                Unidad de Cuidados Intensivos, Hospital General de Zona 1, Instituto Mexicano del Seguro Social , Durango, Mexico
                División de Investigación Clínica, Coordinación de Investigación en Salud, Instituto Mexicano del Seguro Social , Mexico City, Mexico
                División de Investigación Clínica, Coordinación de Investigación en Salud, Instituto Mexicano del Seguro Social , Mexico City, Mexico
                Laboratorio de Microbiología Clínica, Servicio de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , Mexico City, Mexico
                Laboratorio de Microbiología Clínica, Servicio de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán , Mexico City, Mexico
                Dirección de Diagnóstico y Referencia, Instituto de Diagnóstico y Referencia Epidemiológicos, Secretaría de Salud , Mexico City, Mexico
                Mycotic Diseases Branch, Centers for Disease Control and Prevention , Atlanta, Georgia, USA
                Unidad de Educación e Investigación, Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social , Mexico City, Mexico
                Coordinación de Investigación en Salud, Dirección de Prestaciones Médicas, Instituto Mexicano del Seguro Social , Mexico City, Mexico
                Dirección General, Instituto Mexicano del Seguro Social , Mexico City, Mexico
                Dirección General, Secretaría de Salud , Mexico City, Mexico
                Author notes

                G. G.-R. and C. D.-M. contributed equally to this work.

                Potential conflicts of interest. The authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

                Correspondence: Jorge Carlos Alcocer-Varela, MD, PhD, Dirección de la Secretaría de Salud, Homero 213 Piso 19, Col. Chapultepec Morales, Alcaldía Miguel Hidalgo, C.P. 11570, Mexico City, Mexico ( jorge.alcocer@ 123456salud.gob.mx ).
                Article
                ofad690
                10.1093/ofid/ofad690
                10873708
                38370296
                17713788-671b-4d9a-a535-211b409abca1
                © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 01 November 2023
                : 21 December 2023
                : 02 January 2024
                : 16 February 2024
                Page count
                Pages: 9
                Funding
                Funded by: Mexican Ministry of Health;
                Categories
                Outbreak Investigations
                Major Article
                AcademicSubjects/MED00290
                Editor's Choice

                Comments

                Comment on this article